Metagenomi Therapeutics Inc Share Price Today: Live Updates & Key Insights

Metagenomi Therapeutics Inc share price today is $1.44, up -3.4%. The stock opened at $1.47 against the previous close of $1.47, with an intraday high of $1.47 and low of $1.39.

Metagenomi Therapeutics Inc Share Price Chart

Metagenomi Therapeutics Inc

us-stock
To Invest in {{usstockname}}
us-stock

Metagenomi Therapeutics Inc Share Price Performance

$1.44 -0.034(-3.4%) MGX at 23 Mar 2026 02:16 PM Biotechnology
Lowest Today 1.39
Highest Today 1.47
Today’s Open 1.47
Prev. Close 1.47
52 Week High 3.95
52 Week Low 1.23
Day’s Range: Low 1.39 High 1.47
52-Week Range: Low 1.23 High 3.95
1 day return -
1 Week return -6.04
1 month return -0.7
3 month return -20.45
6 month return -39.91
1 year return -15.15
3 year return -
5 year return -
10 year return -

Metagenomi Therapeutics Inc Institutional Holdings

Metagenomi Therapeutics Inc Market Status

Strong Buy: 4

Buy: 2

Hold: 1

Sell: 0

Strong Sell: 0

Metagenomi Therapeutics Inc Fundamentals

Market Cap 53.42 M

PB Ratio 0.3463

PE Ratio 0.0

Enterprise Value -66.72 M

Total Assets 221.10 M

Volume 182303

Metagenomi Therapeutics Inc Company Financials

Annual Revenue FY23:44756000 44.8M

Annual Profit FY23:null 0.0M

Annual Net worth FY23:-68255000 -68.3M

Quarterly Revenue Q3/2025:8659000 8.7M, Q2/2025:8513000 8.5M, Q1/2025:4127000 4.1M, Q3/2024:11514000 11.5M, Q2/2024:20008000 20.0M

Quarterly Profit Q3/2025:7335000 7.3M, Q2/2025:-13994000 -14.0M, Q1/2025:4127000 4.1M, Q3/2024:11514000 11.5M, Q2/2024:18699000 18.7M

Quarterly Net worth Q3/2025:-20393000 -20.4M, Q2/2025:-19908000 -19.9M, Q1/2025:-25039000 -25.0M, Q3/2024:-18773000 -18.8M, Q2/2024:-10739000 -10.7M

About Metagenomi Therapeutics Inc & investment objective

Company Information Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.

Organisation Biotechnology

Employees 119

Industry Biotechnology

CEO Dr. Jian Irish M.B.A., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Metagenomi Therapeutics Inc FAQs

What is the share price of Metagenomi Therapeutics Inc today?

The current share price of Metagenomi Therapeutics Inc is $1.44.

Can I buy Metagenomi Therapeutics Inc shares in India?

Yes, Indian investors can buy Metagenomi Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Metagenomi Therapeutics Inc shares in India?

You can easily invest in Metagenomi Therapeutics Inc shares from India by:

Can I buy fractional shares of Metagenomi Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Metagenomi Therapeutics Inc?

Metagenomi Therapeutics Inc has a market cap of $53.42 M.

In which sector does Metagenomi Therapeutics Inc belong?

Metagenomi Therapeutics Inc operates in the Biotechnology sector.

What documents are required to invest in Metagenomi Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Metagenomi Therapeutics Inc?

The PE ratio of Metagenomi Therapeutics Inc is N/A and the PB ratio is 0.35.